31 Mar 20
tranScrip is pleased to note that Synairgen has confirmed commencement of first patient dosing in a trial of SNG001 in COVID-19.
tranScrip continues to support Synairgen in this important endeavour, a continuation of being at the heart of the development of SNG001 (inhaled formulation of interferon-beta-1a) for the last 12 years.
We have teams of life science and R&D experts to help achieve your goals and seize opportunities. Whatever your project requires, we have the people to meet your needs.